http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020135318-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b92ab46c7a3b0ac716c566ef715cc59 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate | 2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a4a176a0e6520880d17948428ce5254 |
| publicationDate | 2020-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020135318-A1 |
| titleOfInvention | Application of cd38 inhibitor in preparation of anti-rheumatoid arthritis drug |
| abstract | Provided is an application of a CD38 inhibitor in the preparation of an anti-rheumatoid arthritis (RA) drug. Studies have shown that the CD38+NK cell content and the ratio of CD38+NK / CD38+NKT in the blood and synovial fluid of an RA patient are increased, and such change is positively correlated with the DAS28 of the patient, indicating that CD38+NK cells and CD38+NKT cells are expected to become the therapeutic target of RA. Further research clearly shows that high levels of CD38+NK and a high ratio of CD38+NK / CD38+NKT in RA can reduce TGF-β secretion and activate the mTOR pathway of CD4+T cells in MNC, inhibiting the differentiation of CD4+T cells to differentiate Treg cells and IL-10 expression, increase the level of IFN-γ and the ratios of Thl/Th2 and Thl7/Treg, resulting in reduced anti-inflammatory and immune tolerance and exacerbating the course of RA. |
| priorityDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 468.